Logo image of BTAI

BIOXCEL THERAPEUTICS INC (BTAI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BTAI - US09075P2048 - Common Stock

2.05 USD
+0.03 (+1.49%)
Last: 1/13/2026, 8:00:01 PM
2.0399 USD
-0.01 (-0.49%)
After Hours: 1/13/2026, 8:00:01 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BTAI. BTAI was compared to 528 industry peers in the Biotechnology industry. BTAI has a bad profitability rating. Also its financial health evaluation is rather negative. BTAI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BTAI has reported negative net income.
BTAI had a negative operating cash flow in the past year.
BTAI had negative earnings in each of the past 5 years.
In the past 5 years BTAI always reported negative operating cash flow.
BTAI Yearly Net Income VS EBIT VS OCF VS FCFBTAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

BTAI's Return On Assets of -152.28% is on the low side compared to the rest of the industry. BTAI is outperformed by 84.85% of its industry peers.
Industry RankSector Rank
ROA -152.28%
ROE N/A
ROIC N/A
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTAI Yearly ROA, ROE, ROICBTAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

BTAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTAI Yearly Profit, Operating, Gross MarginsBTAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

1

2. Health

2.1 Basic Checks

BTAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BTAI has been increased compared to 1 year ago.
The number of shares outstanding for BTAI has been increased compared to 5 years ago.
Compared to 1 year ago, BTAI has a worse debt to assets ratio.
BTAI Yearly Shares OutstandingBTAI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
BTAI Yearly Total Debt VS Total AssetsBTAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -25.44, we must say that BTAI is in the distress zone and has some risk of bankruptcy.
BTAI's Altman-Z score of -25.44 is on the low side compared to the rest of the industry. BTAI is outperformed by 85.23% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -25.44
ROIC/WACCN/A
WACC9.14%
BTAI Yearly LT Debt VS Equity VS FCFBTAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 1.17 indicates that BTAI should not have too much problems paying its short term obligations.
With a Current ratio value of 1.17, BTAI is not doing good in the industry: 84.85% of the companies in the same industry are doing better.
A Quick Ratio of 1.16 indicates that BTAI should not have too much problems paying its short term obligations.
The Quick ratio of BTAI (1.16) is worse than 84.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 1.16
BTAI Yearly Current Assets VS Current LiabilitesBTAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.93% over the past year.
The Revenue for BTAI has decreased by -66.96% in the past year. This is quite bad
EPS 1Y (TTM)71.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.42%
Revenue 1Y (TTM)-66.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.21%

3.2 Future

The Earnings Per Share is expected to grow by 15.11% on average over the next years. This is quite good.
The Revenue is expected to grow by 151.92% on average over the next years. This is a very strong growth
EPS Next Y74.67%
EPS Next 2Y37.01%
EPS Next 3Y23.81%
EPS Next 5Y15.11%
Revenue Next Year-79.33%
Revenue Next 2Y5.83%
Revenue Next 3Y127.89%
Revenue Next 5Y151.92%

3.3 Evolution

BTAI Yearly Revenue VS EstimatesBTAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
BTAI Yearly EPS VS EstimatesBTAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BTAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BTAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTAI Price Earnings VS Forward Price EarningsBTAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTAI Per share dataBTAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as BTAI's earnings are expected to grow with 23.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.01%
EPS Next 3Y23.81%

More info and screens

0

5. Dividend

5.1 Amount

BTAI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOXCEL THERAPEUTICS INC

NASDAQ:BTAI (1/13/2026, 8:00:01 PM)

After market: 2.0399 -0.01 (-0.49%)

2.05

+0.03 (+1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-25 2026-03-25/amc
Inst Owners12.08%
Inst Owner Change0%
Ins Owners2.05%
Ins Owner Change11.4%
Market Cap44.83M
Revenue(TTM)752.00K
Net Income(TTM)-68.21M
Analysts78.18
Price Target16.12 (686.34%)
Short Float %4.68%
Short Ratio1.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-55.46%
Min EPS beat(2)-81.51%
Max EPS beat(2)-29.42%
EPS beat(4)2
Avg EPS beat(4)3.13%
Min EPS beat(4)-81.51%
Max EPS beat(4)77.91%
EPS beat(8)5
Avg EPS beat(8)15.2%
EPS beat(12)5
Avg EPS beat(12)3.84%
EPS beat(16)7
Avg EPS beat(16)3.18%
Revenue beat(2)0
Avg Revenue beat(2)-53.86%
Min Revenue beat(2)-54.79%
Max Revenue beat(2)-52.94%
Revenue beat(4)0
Avg Revenue beat(4)-54.59%
Min Revenue beat(4)-61.4%
Max Revenue beat(4)-49.22%
Revenue beat(8)2
Avg Revenue beat(8)-35.61%
Revenue beat(12)2
Avg Revenue beat(12)-39.69%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.59%
EPS NQ rev (1m)-6.86%
EPS NQ rev (3m)-10.47%
EPS NY rev (1m)-8.15%
EPS NY rev (3m)-21.55%
Revenue NQ rev (1m)-12.5%
Revenue NQ rev (3m)-40.07%
Revenue NY rev (1m)-6.52%
Revenue NY rev (3m)-26.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 59.62
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.7
EYN/A
EPS(NY)-3.19
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.66
OCFYN/A
SpS0.03
BVpS-4.07
TBVpS-4.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -152.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 1.16
Altman-Z -25.44
F-Score2
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.42%
EPS Next Y74.67%
EPS Next 2Y37.01%
EPS Next 3Y23.81%
EPS Next 5Y15.11%
Revenue 1Y (TTM)-66.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.21%
Revenue Next Year-79.33%
Revenue Next 2Y5.83%
Revenue Next 3Y127.89%
Revenue Next 5Y151.92%
EBIT growth 1Y32.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.68%
EBIT Next 3Y0.54%
EBIT Next 5Y18.97%
FCF growth 1Y65.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.1%
OCF growth 3YN/A
OCF growth 5YN/A

BIOXCEL THERAPEUTICS INC / BTAI FAQ

Can you provide the ChartMill fundamental rating for BIOXCEL THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to BTAI.


Can you provide the valuation status for BIOXCEL THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to BIOXCEL THERAPEUTICS INC (BTAI). This can be considered as Overvalued.


What is the profitability of BTAI stock?

BIOXCEL THERAPEUTICS INC (BTAI) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for BTAI stock?

The Earnings per Share (EPS) of BIOXCEL THERAPEUTICS INC (BTAI) is expected to grow by 74.67% in the next year.